Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_23-46-Cristina Caleja

http://benthamscience.com/journals/current-pharmaceutical-design/

New Issue :: Current Pharmaceutical Design 23, Issue 4

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

CPD

Articles from the journal Current Pharmaceutical Design 23, Issue 4:

                       For details on the articles, please visit this link :: http://bit.ly/2p0Uoer

 

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_23-46-Isabel C.F.R. Ferreira

http://benthamscience.com/journals/current-pharmaceutical-design/

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_23-46-Jose Correa-Basurto

http://benthamscience.com/journals/current-pharmaceutical-design/

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_23-46-Ursula Wyneken

http://benthamscience.com/journals/current-pharmaceutical-design/

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_23-46-Koji Takeuchi

http://benthamscience.com/journals/current-pharmaceutical-design/

Press Release for EurekAlert! Non-ambient conditions in the investigation and manufacturing of drug forms

To become a drug, a pharmacologically active compound must be prepared in a specific form. This form must be robust during manufacturing, packaging, storage and transport, and must administer the correct dose to the patient. To successfully prepare a drug form, one often needs to produce solid samples with controlled crystal structure and a specific particle size and shape. To further complicate matters, these compounds, these drug particles must often end up as a part of a multi-component composite. The present review summarizes how extreme pressure and temperature conditions help achieve this highly tuned material.

In modern culture, it is very rare to find an individual who has never taken any form of medication. It must follow that the pharmaceutical industry is required to produce an enormous quantity of drug products, which can take a variety of different forms: solutions for injections, inhalation powders, sprays, tablets, ointments, patches, amongst others. In many cases, although adopting different administration routes, different trade names are used to market the very same active pharmaceutical ingredient (API). This begs the question: if these products are the same API, is there any difference in which form is taken?

Quite simply put, yes.

Drug molecules move around the body and, by necessity, act at the molecular level. However, many of these compounds are manufactured as solids, which must either be dissolved prior to injection, or are expected to dissolve on digestion in biological fluids. In either case, dissolution is required to release individual molecules into the body.

Solid pharmaceuticals containing the same API (either pure or with additives) can have different crystal structures (polymorphism) or be amorphous. Additionally, solid particles can differ in size, shape, meso-structure, and surface charge. Within the bulk material, the spatial distribution of an API and the additives can vary. Control of these, and many other, characteristics is within the scope of materials sciences and solid-state chemistry. The chemical and material properties of their physical form therefore needs to be identified and optimized for in vivo performance, reliable manufacture and the protection of intellectual property.

Drugs are materials, not simply molecules [1-12], By viewing drugs in this way, one can apply the knowledge of solid-state chemistry, materials science and non-ambient conditions to obtain solid forms with optimized properties. These conditions include, among others, different types of mechanical and ultrasonic treatment, hydrostatic compression, high-temperature or cryogenic spray-drying, and crystallization from supercritical solvents. Solid-state reactions (e.g. dehydration or clathrate decomposition) can be efficient in accessing metastable polymorphs or in uniformly micronizing the sample. To achieve control over drug forms and the processes used for their robust manufacturing, one needs to account for both the thermodynamic and kinetic aspects of their transformations.

The review contains over 400 references and provides a comprehensive guide through the vast ocean of publications in this field. This work is based on the personal experience of the author over several decades of active research.

For more information visit: http://benthamscience.com/journals/current-pharmaceutical-design/volume/22/issue/32/page/4981/

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

Kaja Blagotinšek

https://benthamscience.com/journals/current-pharmaceutical-design/

New Issue :: Current Pharmaceutical Design 23, Issue 5

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

CPD

Articles from the journal Current Pharmaceutical Design 23, Issue 5:


For details on the articles, please visit this link :: 
http://bit.ly/2nToM4R

 

 

SMi EVENT – BioBanking 2017!

SMi is delighted to announce its 7th Annual conference on BioBanking taking place in London, UK on the 14th and 15th of June 2017.

200X200

SMi’s 7th annual conference on Biobanking will bring together Europe’s leading biorepositories, regulatory representatives and scientific pioneers to strengthen knowledge in biosample management as well as explore future advances in areas such as mobile bio-banking and cloud based sample management. Understanding the ethical and regulatory framework as well as the impact of the General Data Protection Regulation (GDPR) on collaborative science in Europe will be a major focus. Plus, don’t miss keynote addresses from a selection of European biobanks currently adding value to clinical research through successful biobanking strategies including the European Sperm Bank, UK Biobank, UCL Baby Biobank, Auria Biobank and more.

Exclusive updates from the European Commission and NIBSC-MHRA, will be just some of the event highlights for 2017. Join us this June for innovative discussions through a series of interactive presentations, panel discussions and roundtables, and address relevant and critical issues on how to improve your biobanking practice.

For details visit the website at http://www.bio-banking-event.com/bentham or contact the team on Tel: +44 (0)20 7827 6000 / Email: events@smi-online.co.uk

Journal: Current Pharmaceutical Design

EBook: Frontiers in Drug Design & Discovery